Marisa Wexler, MS, senior science writer —

Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in bone marrow. Nanoparticle-mediated delivery of an RNA therapy specifically designed to reduce levels of CKAP5 — a protein required for cancer cells to grow and…

The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite Pharma are co-developing for people with relapsed and refractory multiple myeloma (rrMM), following the death of a patient enrolled in the trial. The move pauses the…

Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines of therapy and failed to respond to standard Revlimid (lenalidomide). That’s according to the first data analysis, at nearly 1.5 years of follow-up,…

Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost three years, on average, in people with relapsed or refractory — hard-to-treat — multiple myeloma, according to updated data from a Phase 3 clinical trial.

Survival outcomes for people with multiple myeloma have improved substantially over the last two decades, likely due to the availability of new, more effective treatments, according to a population-based study from Germany. Myeloma itself was the most common cause of death. But the new data also showed that people…

The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene vicleucel) to be given earlier to people with hard-to-treat multiple myeloma. An FDA decision is expected by Dec. 16, according to Abecma’s developers…

The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by Caribou Biosciences for people with relapsed or refractory multiple myeloma. Fast track status is given to investigational treatments with the potential to fill an…

More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a new study. “We have generated artificial mice that accurately reflect key aspects of the origin and development of multiple myeloma in humans,” Marta Larráyoz, the…

Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new study shows. “We’ve found that blocking the FABPs can prevent the growth of myeloma cells, mainly by slowing the cells’ proliferation [growth rate],” Michaela Reagan,…

Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory multiple myeloma. “We look forward to working closely with the FDA in their review of the talquetamab submission,” Peter Lebowitz, MD, PhD, global oncology…